



Patient Empowerment through Education

LUNGEVITY'S VISION

**A world where no one dies
of lung cancer.**

LUNGEVITY GOALS

We accomplish this through:

- **Accelerate research to patients**
- **Empower patients to participate in treatment decision making**
- **Help eliminate barriers to access treatments**

LUNGEVITY'S THREE PILLARS

We accomplish this through:

- Funding research
- Providing comprehensive education and support services
- Working with policy, regulatory and other partners to improve timely access to treatments

FOCUS ON EMPOWERING THROUGH EDUCATION

Patient Empowerment

Philosophy that patients are active participants in, not passive recipients of, the caring process,


and thus should be well informed about all aspects of their health, 'wellness status' and disease state,

to gain maximum health benefit

~ World Health Organization

DIKU

(DATA-INFORMATION-KNOWLEDGE-UNDERSTANDING)



OLD WEBSITE – WHAT WE DO



LUNGevity
Find it. Treat it. Live.

ABOUT US | ABOUT LUNG CANCER | RESEARCH | EVENTS | ASK THE EXPERTS | WAYS TO GIVE | NEWSROOM | SUPPORT & ADVOCACY | BLOG

LUNGevity ADVOCATES

"I'm hopeful that together we can really change the outlook for lung cancer patients and their families."

[CONTINUE](#)

LUNGevity News

LUNGevity lost a very special person with the passing of Monica Barlow, public relations director for the Baltimore Orioles. Monica was a friend, a survivor, and an extraordinary ally in the daily battle our organization and others fight against this disease.

The pain of losing her is fresh and sharp, but what we will remember always is the indomitable courage she showed as she battled lung cancer. She was determined that her life would not be defined by lung cancer, and in living her life to the fullest extent possible she inspired countless others to do the same. She selflessly gave of her time and energy to help people understand the reality of lung cancer and to raise money for critical research that can stop the disease from extracting the terrible toll it takes every year.

Survivor part of Monica's legacy lies in the hope she believed in, and provided. Hope that one day we will live in a world where no one, let alone a healthy, vital, athletic 32 year old, will end up dying far too soon from lung cancer. Hope that we will marshal the energy, resources and will to make lung cancer a national priority. Monica invested herself in that

LUNGevity SERVICES

Innovative research
Working toward earlier detection and more effective treatments of lung cancer, LUNGevity-funded research projects have totaled almost \$26 million, with 100 projects at 26 institutions in 23 states.

Ask the Experts
Up-to-date, medically expert information from health care professionals

Survivor Resource Center
Information for survivors at any stage of their lung cancer journey

Caregiver Resource Center
Information for those caring for people with lung cancer

Online Support
Connect with other patients, survivors, caregivers and experts

Events Coast to Coast
A national network of awareness

LUNGevity HERO

LUNGevity Hero: Doug Kammerer

It is with great excitement that we launch our monthly LUNGevity Hero spotlight to honor some of our most important allies in our fight against lung cancer.


PODCASTS, VIDEOS, AND WEBINARS

Webinar Library

- Lung Cancer Highlights 2012**, Dr. Mutsaers Leigh, Princess Margaret Hospital and University of Toronto
- Small Cell Lung Cancer**, Dr. Arzoo Wazirak, Karmanos Cancer Center at Wayne State University
- Refining Prognosis of Early Stage Lung Cancer by Molecular Features**, Dr. Johannes Krutz, Massachusetts General Hospital
- Advances in Surgery for Lung Cancer**, Dr. David Harpole, Duke University Medical Center
- Practical Aspects of Clinical Trials in Cancer: Myths and Facts**, Dr. Suresh Ramalingam, Winship Cancer Center at Emory University
- Molecular Pathology in Lung Cancer**, Dr. Dana Aisner, Colorado Molecular Correlates Laboratory and University of Colorado
- New Radiation Techniques for Lung Cancer**, Dr. Vivek Harth, Swedish Cancer Institute
- ASCO Conference 2012 Review**, Dr. Joel Teal, Stanford University, and Dr. Mark Socinski, University of Pittsburgh
- Managing Pulmonary Complications in Lung Cancer**, Dr. Gerard Silvestri, Medical University

Video Library

- Targeted Therapies in Lung Cancer Conference: The Mx Cancer Genome Project**, Dr. William Pea, Vanderbilt University
- What is an inherited EGFR T790M mutation and what does it mean?**, Dr. Geoffrey Harland, Farber Cancer Institute
- Molecular marker testing in ad what, who, and when?**, Dr. Lecl, Massachusetts General Hospital
- What are the most promising 5 for lung cancer in the next five Spigel, Sarah Cannon Cancer C**
- How should we approach novel targeted therapies in advanced Riley, Memorial Sloan-Kettering**
- How should we use molecular information in earlier stage NCI Wakelee, Stanford University**
- What molecular markers do us for in your patients with aduan Karen Kelly, University of Calif**
- How do you discuss the pros and cons of molecular testing, with potential delays and need for reassess?**, Dr. Sarah Goldberg, Yale School of Medicine



ASK THE EXPERTS

ASK THE EXPERTS

Experts Blog

LUNGevity's Ask the Expert

About the Experts

Podcasts/Webinars

General

Search Answers

Begin your search here. Use the form below to search existing answers for your questions.

Search terms: Select a category:

I have episodes where it feels like my breath is being snatched away, it only last 1 second or so but it is worrisome. Should I have this checked out? I have had complete Physical and no problems with the exception of seasonal asthma.

I'd like to know whether there was any effective alternative treatment that you are aware of, or any research into alternative treatments that anyone has or is considering funding?

My mum has just be diagnosed with Lung cancer for a 2nd time.

THE LUNGevity EXPERT BLOG

Archive for the 'Immunotherapy' Category

5 Key Points on Immune Checkpoint Inhibitors for Lung Cancer: Game Changer or Just Leveling Up?

January 6th, 2014 - by Dr. Jack West




Just last week, I ranked the development of immunotherapies as the leading development in lung cancer in 2013. I don't consider 2013 to be the clear turning point for immunotherapies in lung cancer; they have been the subject of interest and research for many years, and ASCO 2012 really marks their breakout from niche idea to more widespread credibility. But if 2012 was the real launchpad, 2013 saw the rocket

NEW WEBSITE – PATIENT RESOURCE



[DONATE NOW](#)



- [ABOUT LUNG CANCER](#) ▾
- [THE RESEARCH WE FUND](#) ▾
- [SUPPORT & SURVIVORSHIP](#) ▾
- [EVENTS](#) ▾
- [ABOUT US](#) ▾
- [GET INVOLVED](#) ▾



LUNG CANCER 101: a COMPREHENSIVE educational resource

[Get started](#) 


 **LEARN**
from our experts

 **CONNECT**
with our community

 **DONATE**
to support research

 **GET INVOLVED**
Make a difference!

EMPOWERING PATIENTS THROUGH EDUCATION – WEBSITE



The screenshot displays the LUNGevity website interface. At the top left is the LUNGevity logo with the tagline "Find it. Treat it. Live." and an orange "DONATE" button. To the right is a search bar with a magnifying glass icon and three font size adjustment icons. Below the logo is a navigation menu with items: "ABOUT LUNG CANCER", "THE RESEARCH WE FUND", "SUPPORT & SURVIVORSHIP", "EVENTS", "ABOUT US", and "GET INVOLVED".

The main content area is divided into three columns:

- LUNG CANCER 101**
 - HOW LUNG CANCER DEVELOPS
 - REDUCING YOUR RISK
 - SCREENING & EARLY DETECTION
 - SIGNS & SYMPTOMS
 - DIAGNOSING LUNG CANCER
 - TYPES OF LUNG CANCER
 - LUNG CANCER STAGING
 - YOUR MEDICAL TEAM
 - TREATMENT OPTIONS
 - CLINICAL TRIAL FINDER
- EXPERTS BLOG**
 - LUNG CANCER IN THE NEWS
 - LUNG CANCER STATISTICS
 - SEE ALSO ...
 - LIVING WELL WITH LUNG CANCER
- VIDEO LIBRARY**
 - ADDITIONAL RESOURCES
 - GLOSSARY


Below the navigation are two content cards:

- ASKING THE RIGHT QUESTIONS**: Includes an image of a doctor and patient, the text "Knowing what questions to ask can help you get the best treatment for your type of lung cancer.", and a "DOWNLOAD OUR TIP SHEETS" button.
- EDUCATIONAL MATERIALS**: Includes an image of educational materials, the text "LUNGevity has a variety of educational materials available to download or to order at no charge.", and a "GET EDUCATIONAL MATERIALS" button.

At the bottom, there is a "PRINT THIS PAGE" button and a map of the United States.

EMPOWERING PATIENTS THROUGH EDUCATION – WEBSITE

ABOUT LUNG CANCER ▾ THE RESEARCH WE FUND ▾ SUPPORT & SURVIVORSHIP ▾ EVENTS ▾ ABOUT US ▾ DONATE ▾



ABOUT LUNG CANCER

[Home > About Lung Cancer >](#)

Lung Cancer 101

Lung Cancer 101 is your comprehensive guide through lung cancer diagnosis and treatment. Whether you have recently been diagnosed with lung cancer, or someone you care about has been, or you are concerned about your own risk, we have resources to help you.


You can start at the beginning, or skip through to the parts that are currently most relevant to you. Some sections contain a lot of scientific and technical information for those who want to understand the underlying mechanisms of lung cancer and its treatment; other sections focus on practical information and questions you can ask your doctors. (Be sure you also visit [Asking the Right Questions](#) for complete printable lists of questions you can take with you to doctor visits.)

Once you are familiar with your diagnosis and treatment options, you will find many kinds of caring and supportive assistance in the [Support and Advocacy](#) section.


How Lung Cancer Develops	Signs and Symptoms	Lung Cancer Staging
Reducing Your Risk	Diagnosing Lung Cancer	Your Medical Team
Screening and Early Detection	Types of Lung Cancer	Your Treatment Plan

Additional Resources
Glossary


PATIENT EMPOWERMENT – COMPREHENSIVE APPROACH



The screenshot shows the LUNGevity website with a navigation menu including 'ABOUT LUNG CANCER', 'THE RESEARCH WE FUND', 'SUPPORT & SURVIVORSHIP', 'EVENTS', 'ABOUT US', and 'GET INVOLVED'. The main content area is titled 'ABOUT LUNG CANCER' and features a large image of a chest X-ray. A sidebar on the left lists various topics like 'Lung Cancer 101', 'How Lung Cancer Develops', and 'Reducing Your Risk'. The main text area is titled 'Clinical Trials' and includes a 'TIP...' section and a 'FIND A CLINICAL TRIAL NEAR YOU' button.




This section is titled 'LUNG CANCER TREATMENTS' and features a sub-header 'What you need to know about... clinical trials patient-assisted research studies'. It includes several circular portraits of diverse individuals. At the bottom right of this section is the LUNGevity logo.



This section is titled 'Questions about clinical trials' and contains a list of seven numbered questions with horizontal lines for answers:

- How do I know if I am a possible candidate for a clinical trial?
- Are clinical trials only for people who have failed all other options?
- If I am a candidate to receive an approved standard therapy, why should I participate in a clinical trial?
- Are clinical trials safe?
- What are some of the risks and benefits of participating in a clinical trial?
- What is the goal of this trial? Who is sponsoring it?
- What is known about the investigational drug being studied? Has it worked in previous trials? Is it the same as chemotherapy?
- How will I be given the drug? How often and for how long?
- Are there tests to determine if I am eligible for this trial?



PATIENT TOOLS CLINICAL TRIAL FINDER

STUDY FINDER - STUDIES - BEFORE SCREENING



Find A Study That Is Right For You

We Found **185** Lung Cancer Studies.

SEARCH FILTERS:

- SEARCH BY: Search by Keyword
- SEARCH BY: Disease
- SEARCH BY: Location
- SEARCH BY: Study Type
- SEARCH BY: Study Phase
- SEARCH BY: Study Status
- SEARCH BY: Study Sponsor
- SEARCH BY: Study Start Date
- SEARCH BY: Study End Date
- SEARCH BY: Study Age Range
- SEARCH BY: Study Gender
- SEARCH BY: Study Conditions
- SEARCH BY: Study Location

STUDY RESULTS:

- Pembrolizumab in Advanced NSCLC w/ RCT Translational**
 - Study Type: Phase 3
 - Study Status: Open
 - Study Sponsor: Merck
 - Study Start Date: 2017
 - Study End Date: 2020
 - Study Age Range: 18 to 75
 - Study Gender: Male, Female
 - Study Conditions: Advanced Non-Small Cell Lung Cancer
 - Study Location: Multiple Locations
- Sunitinib Toxicity with or without Docetaxel in Hydronephrosis**
 - Study Type: Phase 2
 - Study Status: Open
 - Study Sponsor: Genentech
 - Study Start Date: 2017
 - Study End Date: 2020
 - Study Age Range: 18 to 75
 - Study Gender: Male, Female
 - Study Conditions: Hydronephrosis
 - Study Location: Multiple Locations
- Radiation Therapy With or Without Trastuzumab in Treating Women with Breast Cancer**
 - Study Type: Phase 3
 - Study Status: Open
 - Study Sponsor: Genentech
 - Study Start Date: 2017
 - Study End Date: 2020
 - Study Age Range: 18 to 75
 - Study Gender: Female
 - Study Conditions: Breast Cancer
 - Study Location: Multiple Locations
- Safety and Efficacy Study of Apremilast in Combination with Sunitinib**
 - Study Type: Phase 2
 - Study Status: Open
 - Study Sponsor: Genentech
 - Study Start Date: 2017
 - Study End Date: 2020
 - Study Age Range: 18 to 75
 - Study Gender: Male, Female
 - Study Conditions: Hydronephrosis
 - Study Location: Multiple Locations
- LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer**
 - Study Type: Phase 3
 - Study Status: Open
 - Study Sponsor: Genentech
 - Study Start Date: 2017
 - Study End Date: 2020
 - Study Age Range: 18 to 75
 - Study Gender: Male, Female
 - Study Conditions: Advanced Non-Small Cell Lung Cancer
 - Study Location: Multiple Locations

STUDY FINDER - STUDIES - AFTER SCREENING



Not Finding a Study For You?

Study Details

STUDY FINDER - STUDIES - SCREENING PAGE



Fill In The Fields Below, And We Will Help You Find a Study That Matches Your Information.

- Select Your Year of Birth
- Select Your Gender
 MALE FEMALE
- Add Your Conditions
- Where Are You Located?



Ready To See Which Studies You Match We'll Wait?



Sorafenib Toxicity With or Without Docetaxel in Hydronephrosis

Safety and Efficacy Study of Apremilast in Combination with Sunitinib

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer

STUDY DETAILS



Study Details

About This Clinical Study

Study Locations



LESSONS LEARNED

- **It is expensive and it takes a long time**
- **Essential to have input from key stakeholders**
- **Always evolving**
- **Need to provide information in multiple formats, multiple times**
- **Need to ensure that information is getting to the patient**
- **Metrics**